Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Trial details
- Registry ID
- NCT05425940
- Phase
- Phase 3
The FDA approved Regorafenib (Stivarga®) on 27 Sep 2012.
Drug identity checked against registry records
Also recorded as Stivarga®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940 | Exelixis | Phase 3 | Active not recruiting | 2026-06-16Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2012-09-27Day | Regorafenib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA203085", "applicant_as_listed_by_fda": "BAYER HLTHCARE", "brand_names": ["STIVARGA"], "active_ingredients": ["REGORAFENIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20120927", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |